Publication: Molecular Therapy. 24(3): 570-581.
Published Date: March 2016
Assesses ability of three targeted nuclease systems to disrupt off-target cleavage in human T-cells.
Present adoptive immunotherapy strategies are based on the re-targeting of autologous T-cells to recognize tumor antigens. However, donor-derived T-cells have the potential to direct off-tumor antihost reactivity due to endogenous receptors on the cell surface. To address those limitations, the authors assessed the ability of TALENs, CRISPR/Cas9, and megTAL nucleases to disrupt T-cell receptor expression. They found that megaTAL and CRISPR/Cas9 reagents were most efficient and least toxic.